Buy Nephrocare Health Services Ltd For Target Rs. 820 by Choice Institutional Equities
Building a Market-leading Dialysis Care Platform with Structural Advantages: NEPHROPL is well-positioned to benefit from the long-term growth of the dialysis market through its scalable, clinically integrated platform. As India's largest organised dialysis provider, the company is expected to capitalise on rising CKD incidence, expanding insurance coverage and government reimbursement, with India's dialysis patient population projected to expand at a 13% CAGR through 2029. Management has guided for 15–20% revenue CAGR over the next 3–4 years, supported by continued clinic expansion, higher utilisation, brownfield acquisitions and selective international growth. Backed by disciplined capital allocation, strong operating leverage and healthy cash generation, NEPHROPL is expected to improve ROCE, strengthen market leadership and deliver sustainable long-term value-creation
Entering into a Powerful Operating Leverage Cycle with Accelerating Profitability: NEPHROPL is well-positioned to deliver a sustained margin expansion as its network scales up and operating leverage strengthens. Management anticipates recently added clinics to mature, utilisation to improve and international operations to contribute a larger share of revenue, enhancing profitability through better fixed-cost absorption. Guided by a 15–20% revenue CAGR over the next 3–4 years (we are expecting ~21% CAGR over FY26–29E), the company is expected to convert revenue growth into faster EBITDA, PAT and free cash flow growth. Higher utilisation, rising dialysis volumes and a growing international mix will drive revenue per treatment and margin expansion. Disciplined capital allocation, selective acquisitions and technology-led efficiencies are expected to strengthen ROCE, cash-generation and long-term shareholder value.
Investment View: We expect Revenue/EBITDA/PAT to expand at a CAGR of 21.2%/20.6%/41.9% over FY26–29E. The growth will be driven by leadership in India’s dialysis market with resilient recurring revenues, an asset-light model and a strong operating leverage. Its expanding international footprint provides an additional growth engine, with rising overseas contribution supporting revenue growth and improving ROCE. Thus, we initiate coverage on NEPHROPL with a ‘BUY’ rating and a target price of INR 820, with an upside of 32.2%, by valuing the company on DCF, with an implied PE of 41x and implied PEG of 0.98x on an average of FY28–29E EPS
Optionality: Winning tender in the Saudi Arabia market is projected to significantly improve Revenue Per Patient, while accelerating growth and enhancing profitability.
Key risks: Structurally high working capital requirements, dependence on private hospital contract renewals and limited pricing power of the company.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
